Figure 4.

SchB results in the inhibition of the NF-κB and p38 MAPK signaling pathways. Cancer stem-like cells (NCI-H460-CSCs and H661-CSCs) were treated with 10, 20 or 40 µmol/l SchB and the control group was treated with PBS. (A) Protein expression levels of important genes in the NF-κB signaling pathway (IκBα and p65) were examined by western blot analysis. (B) Immunofluorescence assay was used to determine the nuclear translocation of p65 in cancer stem-like cells after SchB treatment. Scale bar, 25 µm. (C) Protein expression levels of JNK, p-JNK, p38, p-p38, MEK and p-MEK were measured by western blot analysis. Differences were analyzed by one-way ANOVA with Tukey's correction. *P<0.05, **P<0.01 vs. control. SchB, Schisandrin B; IκBα, inhibitor of nuclear factor κ Bα; p, phosphorylated.